JWBC
NKTR icon

John W. Brooker & Co’s Nektar Therapeutics NKTR Stock Holding History

John W. Brooker & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed – – 140
2022
Q3 		$0 Hold
3
– – ﹤0.01% 195
2022
Q2 		$0 Hold
3
– – ﹤0.01% 196
2022
Q1 		$0 Hold
3
– – ﹤0.01% 198
2021
Q4 		$1K Hold
3
– – ﹤0.01% 186
2021
Q3 		$1K Hold
3
– – ﹤0.01% 182
2021
Q2 		$1K Hold
3
– – ﹤0.01% 184
2021
Q1 		$2K Hold
3
– – ﹤0.01% 159
2020
Q4 		$1K Hold
3
– – ﹤0.01% 157
2020
Q3 		$1K Hold
3
– – ﹤0.01% 156
2020
Q2 		$1K Hold
3
– – ﹤0.01% 159
2020
Q1 		$1K Hold
3
– – ﹤0.01% 165
2019
Q4 		$1K Buy
+3
New +$870 ﹤0.01% 158

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

John W. Brooker & Co's NKTR Position: Q4 2022 in Review

John W. Brooker & Co sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 3 shares.

John W. Brooker & Co first reported a position in NKTR in Q4 2019 and held it in 12 quarters. The position peaked at $2K in Q1 2021. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • John W. Brooker & Co reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • John W. Brooker & Co sold 3 Nektar Therapeutics shares in Q4 2022.
  • John W. Brooker & Co first reported a position in Nektar Therapeutics in Q4 2019 and held it in 12 quarters.
  • John W. Brooker & Co's Nektar Therapeutics position peaked at $2K in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on John W. Brooker & Co's 13F filing for Q4 2022, filed 13 Jan 2023.